98%
921
2 minutes
20
Background: Paragangliomas are rare neuroendocrine tumors that can manifest with endocrinological symptoms from excessive catecholamine secretion and symptoms from mass effect depending on biochemical behavior and tumor location.
Methods: Following an encounter with a patient with a rare case of paraganglioma of the thoracic spine, a systematic review was performed of patients with a diagnosis of paraganglioma and SDHB mutation. Inclusion criteria were met by 14 studies for a total of 66 patients.
Results: A 55-year-old man with a known history of treated metastatic paraganglioma with SDHB mutation presented with progressive weakness in his extremities. He was found to have significant spinal cord compression from a lesion localized to T1-T3 vertebrae with vertebral body as well as epidural involvement. This area was previously treated with laminectomy and fusion as well as radiotherapy. Given his neurological symptoms and failure of previous radiotherapy treatment, our treatment approach was aggressive multidisciplinary intervention. He successfully underwent endovascular embolization, surgical resection with instrumented fusion, radiotherapy, and chemotherapy with temozolomide to treat this lesion as well as an incidentally located T12 lesion. Given the rarity of this disease, we performed a systematic review of paraganglioma with SDHB mutation, which demonstrated a wide variety of treatment options.
Conclusions: Although metastatic/multifocal paragangliomas are rare, their occasional relentless course may require complex multidisciplinary treatment to maximize neurological and oncological outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.wneu.2025.123976 | DOI Listing |
JMIR Hum Factors
September 2025
Seidenberg School of Computer Science and Information Systems, Pace University, New York City, NY, United States.
Background: As information and communication technologies and artificial intelligence (AI) become deeply integrated into daily life, the focus on users' digital well-being has grown across academic and industrial fields. However, fragmented perspectives and approaches to digital well-being in AI-powered systems hinder a holistic understanding, leaving researchers and practitioners struggling to design truly human-centered AI systems.
Objective: This paper aims to address the fragmentation by synthesizing diverse perspectives and approaches to digital well-being through a systematic literature review.
J Med Internet Res
September 2025
School of Pharmacy, Sungkyunkwan University, Gyeonggi-do, Republic of Korea.
Background: Owing to the unique characteristics of digital health interventions (DHIs), a tailored approach to economic evaluation is needed-one that is distinct from that used for pharmacotherapy. However, the absence of clear guidelines in this area is a substantial gap in the evaluation framework.
Objective: This study aims to systematically review and compare the economic evaluation literature on DHIs and pharmacotherapy for the treatment of depression.
JAMA Psychiatry
September 2025
Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville.
Importance: Behavioral variant frontotemporal dementia (bvFTD), the most common subtype of FTD, is a leading form of early-onset dementia worldwide. Accurate and timely diagnosis of bvFTD is frequently delayed due to symptoms overlapping with common psychiatric disorders, and interest has increased in identifying biomarkers that may aid in differentiating bvFTD from psychiatric disorders.
Objective: To summarize and critically review studies examining whether neurofilament light chain (NfL) in cerebrospinal fluid (CSF) or blood is a viable aid in the differential diagnosis of bvFTD vs psychiatric disorders.
JAMA Netw Open
September 2025
Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla.
Importance: Janus kinase (JAK) inhibitors are highly effective medications for several immune-mediated inflammatory diseases (IMIDs). However, safety concerns have led to regulatory restrictions.
Objective: To compare the risk of adverse events with JAK inhibitors vs tumor necrosis factor (TNF) antagonists in patients with IMIDs in head-to-head comparative effectiveness studies.